摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 3-{[3-(acetylamino)propyl]sulfonyloxy}-2,2-dimethylpropanoate | 1131569-69-1

中文名称
——
中文别名
——
英文名称
methyl 3-{[3-(acetylamino)propyl]sulfonyloxy}-2,2-dimethylpropanoate
英文别名
methyl 3-(3-acetamidopropylsulfonyloxy)-2,2-dimethylpropanoate
methyl 3-{[3-(acetylamino)propyl]sulfonyloxy}-2,2-dimethylpropanoate化学式
CAS
1131569-69-1
化学式
C11H21NO6S
mdl
——
分子量
295.357
InChiKey
GSLIZJOKYMYPED-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    510.6±35.0 °C(predicted)
  • 密度:
    1.195±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    19
  • 可旋转键数:
    9
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    107
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

  • 作为产物:
    描述:
    羟基三甲基乙酸甲酯3-乙酰氨基丙烷-1-磺酰氯4-二甲氨基吡啶三乙胺 作用下, 以 二氯甲烷 为溶剂, 以23%的产率得到methyl 3-{[3-(acetylamino)propyl]sulfonyloxy}-2,2-dimethylpropanoate
    参考文献:
    名称:
    MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE
    摘要:
    掩蔽羧酸新戊磺酰酯丙戊酸酯前药,包含此类前药的药物组合物,以及使用此类前药和组合物治疗疾病的方法被披露。具体来说,披露了表现出增强口服生物利用度的丙戊酸酯前药和使用丙戊酸酯前药治疗神经退行性疾病、精神疾病、情绪障碍、焦虑障碍、躯体形式障碍、运动障碍、物质滥用障碍、暴饮暴食障碍、皮层扩散性抑郁相关障碍、耳鸣、睡眠障碍、多发性硬化症和疼痛的方法。
    公开号:
    US20090069419A1
点击查看最新优质反应信息

文献信息

  • [EN] MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE<br/>[FR] PROMÉDICAMENTS D'ACAMPROSATE À LIBÉRATION PAR CYCLISATION SOUS FORME DE NÉOPENTYL-SULFONYLESTERS CARBOXYLATES MASQUÉS, COMPOSITIONS LES COMPRENANT ET MÉTHODES D'UTILISATION CORRESPONDANTES
    申请人:XENOPORT INC
    公开号:WO2009033061A1
    公开(公告)日:2009-03-12
    Masked carboxylate neopentyl sulfonyl ester prodrugs of acamprosate of formula (I), pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorders, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis and pain are disclosed.
  • MASKED CARBOXYLATE NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE
    申请人:Jandeleit Bernd
    公开号:US20090069419A1
    公开(公告)日:2009-03-12
    Masked carboxylate neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.
    掩蔽羧酸新戊磺酰酯丙戊酸酯前药,包含此类前药的药物组合物,以及使用此类前药和组合物治疗疾病的方法被披露。具体来说,披露了表现出增强口服生物利用度的丙戊酸酯前药和使用丙戊酸酯前药治疗神经退行性疾病、精神疾病、情绪障碍、焦虑障碍、躯体形式障碍、运动障碍、物质滥用障碍、暴饮暴食障碍、皮层扩散性抑郁相关障碍、耳鸣、睡眠障碍、多发性硬化症和疼痛的方法。
查看更多